10. 默克

    • 2013年研发支出：75亿美元

    • 占收入的百分比：17%

    这家制药公司总部位于美国新泽西州，最主要的研发投资领域是肿瘤、传染病、疫苗和糖尿病。今年，默克的免疫抗肿瘤药物Keytruda获得美国食品药品监督管理局批文，该药用于治疗晚期黑色素瘤，而后者是一种危险的皮肤癌。该公司负责全球临床开发的高级副总裁罗伊•贝恩斯说：“我们认为Keytruda和免疫抗肿瘤药物让癌症患者的治疗方式发生了根本性变化。”他表示，默克还将把该药的研究拓展至其他30多种癌症。（财富中文网）

    译者：Charlie

    审：李翔

    10. Merck

    • R&D spending in 2013: $7.5 billion

    • As a percentage of revenue: 17%

    The N.J.-based pharmaceutical company lists its top R&D investment priorities as oncology, infectious diseases, vaccines, and diabetes. This year Merck received approval from the FDA for an immuno-oncology drug called Keytruda that treats a dangerous form of skin cancer known as advanced melanoma. “We see Keytruda and immuno-oncology drugs as a fundamental change in how we treat cancer patients,” says Dr. Roy Baynes, senior vice president of global clinical development. Merck is also extending studies of the drug to more than 30 other tumor types, he says.